引用次数
引用: 25,091
H-指数: 68
I10-指数 : 220
出版物: 686
Nab-paclitaxel/Gemcitabine first line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin values-data from the German QoliXane pancreatic cancer registry
G Zur Hausen , O Waidmann , M-A Woerns , H-G Hoeffkes
ONCOLOGY RESEARCH AND TREATMENT 40 259 -259
2
2017
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-a randomized, doubleblind, placebo-controlled, phase 3 study
S-E Al-Batran , Y Janjigian , E Van Cutsem , K Muro
Oncology Research and Treatment 44 218 -218
1
2021
Intravenous ferric carboxymaltose vs. oral iron substitution in patients with metastatic colorectal cancer (mCRC) and iron deficiency anemia: a randomized multicenter treatment optimization study (A Study in Progress Report)
G Zur Hausen , I Roetzer , A Reichart , C Pauligk
Oncology Research and Treatment 39 74 -74
1
2016
Phase I/II, open label, dose escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu (1+/SISH positive, 2+ and 3+) expressing solid tumors progressing after standard therapy
N Haense , M Jaeger , D Klunker , W Hozaeel
ONCOLOGY RESEARCH AND TREATMENT 37 106 -106
1
2014
Home parenteral nutrition (HPN) using individually compounded PN via A 7/8/9-Multi-chamber system versus PN via 2/3-chamber bags in subjects with metastatic or localized solid tumors requiring HPN-The IKF-010 Pekannuss trial
S-E Al-Batran , I Roetzer , L Wohn , W Blau
Clinical Nutrition ESPEN 58 440 -441
2023
Strata A and B of the phase I INSIGHT platform trial evaluating feasibility and safety of intratumoral and intraperitoneal eftilagimod alpha (soluble LAG-3 protein) in advanced stage solid tumors entities
TO Goetze , DW Mueller , M-R Rafiyan , D Kiselicki
ONCOLOGY RESEARCH AND TREATMENT 43 ( SUPPL 4) 232 -232
2020
The phase I INSIGHT platform trial: Safety data from stratum D of evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced stage solid tumor entities
TO Goetze , DW Mueller , M-R Rafiyan , D Kiselicki
ONCOLOGY RESEARCH AND TREATMENT 43 ( SUPPL 4) 232 -233
2020
Diagnostic and prognoses of relapses of gastric and esophageal adenocarcinoma within follow-up care-a retrospective analysis
FK Tauchert , A Strauss-Rothenbuecher , US Bankstahl , T Heidsieck
ONCOLOGY RESEARCH AND TREATMENT 40 317 -317
2017
Early PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration resistant prostate cancer. The non-interventional QoLiTime study
P Hammerer , S-E Al-Batran , C Windemuth-Kieselbach , M Keller
ONCOLOGY RESEARCH AND TREATMENT 40 94 -94
2017
Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: exploratory analyses from RAINBOW and REGARD
S-E Al-Batran , I Chau , C Fuchs , A Ohtsu
ONCOLOGY RESEARCH AND TREATMENT 40 160 -160
2017
Metastatic Pancreatic Cancer: real Life Data from the German Quality of Life and translational research on pancreatic cancer study (QoliXane)
A Reichart , S-E Al-Batran , C Schoenherr , G Zur Hausen
ONCOLOGY RESEARCH AND TREATMENT 40 210 -210
2017
Diagnostic and prognoses of relapses of gastric and esophageal adenocarcinoma within follow-up care-a retrospective analysis
FK Tauchert , A Strauss-Rothenbuecher , US Bankstahl , T Heidsieck
ONCOLOGY RESEARCH AND TREATMENT 39 317 -317
2016
Metastatic Pancreatic Carcinoma: Observational Registry Study on Quality of Life and Molecular Biology of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy-A Study in Progress Report
G Zur Hauser , J Raab , C Pauligk , A Reichart
ONCOLOGY RESEARCH AND TREATMENT 39 82 -82
2016
Quality-of-life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with Cabazitaxel-results from the non-interventional study QoLiTime
S-E Al-Batran , C Lange , T Ecke , C Windemuth-Kieselbach
Oncology Research and Treatment 38 81 -81
2015
Intravenous ferric carboxymaltose vs. oral iron substitution in patients with metastatic colorectal cancer (mCRC) and iron deficiency anemia: a randomized multicenter treatment optimization study (a study in progress report)
G zur Hausen , I Roetzer , A Reichart , C Pauligk
ONCOLOGY RESEARCH AND TREATMENT 38 62 -62
2015
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study
S Hegewisch-Becker , D Arnold , CA Lerchenmueller , B Killing
ONCOLOGY RESEARCH AND TREATMENT 37 99 -99
2014
Metastatic Pancreatic Carcinoma: Observational study on quality of life of patients receiving Nab-paclitaxel/Gemcitabine first line therapy, including a translational program (a study in progress report)
G Zur Hausen , C Pauligk , W Hozaeel , R Hofheinz
ONCOLOGY RESEARCH AND TREATMENT 37 168 -168
2014
Treatment algorithms for adenocarcinomas of the stomach and the gastroesophageal junction
S-E Al-Batran , M Eble , SP Mönig
Der Onkologe 19 352 -353
2013
From" Stepchild" to Classic Example
S-E Al-Batran , PM Schlag
ONKOLOGE 19 ( 5) 350 -350
2013
Cancer patients and the internet-a survey of the quality of life working groups of the AIO and the NOGGO
D Gencer , F Tauchert , N Keilhauer , S-E Al-Batran
ONKOLOGIE 34 42 -42
2011